key: cord-0759081-502fo34g
authors: Matkovic, Zinka; Miravitlles, Marc
title: Chronic bronchial infection in COPD. Is there an infective phenotype?
date: 2012-12-04
journal: Respir Med
DOI: 10.1016/j.rmed.2012.10.024
sha: 163f5cb9d4d18dda324d70d6b3a100c208434941
doc_id: 759081
cord_uid: 502fo34g

Microorganisms, particularly bacteria, are frequently found in the lower airways of COPD patients, both in stable state and during exacerbations. The host–pathogen relationship in COPD is a complex, dynamic process characterised by frequent changes in pathogens, their strains and loads, and subsequent host immune responses. Exacerbations are detrimental events in the course of COPD and evidence suggests that 70% may be caused by microorganisms. When considering bacterial exacerbations, recent findings based on molecular typing have demonstrated that the acquisition of new strains of bacteria or antigenic changes in pre-existing strains are the most important triggers for exacerbation onset. Even in clinically stable COPD patients the presence of microorganisms in their lower airways may cause harmful effects and induce chronic low-grade airway inflammation leading to increased exacerbation frequency, an accelerated decline in lung function and impaired health-related quality of life. Besides intraluminal localisation in the distal airways, bacteria can be found in the bronchial walls and parenchymal lung tissue of COPD patients. Therefore, the isolation of pathogenic bacteria in stable COPD should be considered as a form of chronic infection rather than colonisation. This new approach may have important implications for the management of patients with COPD.

Bacteria; Chronic obstructive pulmonary disease; Phenotypes; Colonisation; Exacerbation; Infection; Microorganisms Summary Microorganisms, particularly bacteria, are frequently found in the lower airways of COPD patients, both in stable state and during exacerbations. The hostepathogen relationship in COPD is a complex, dynamic process characterised by frequent changes in pathogens, their strains and loads, and subsequent host immune responses.

Exacerbations are detrimental events in the course of COPD and evidence suggests that 70% may be caused by microorganisms. When considering bacterial exacerbations, recent findings based on molecular typing have demonstrated that the acquisition of new strains of bacteria or antigenic changes in pre-existing strains are the most important triggers for exacerbation onset.

Even in clinically stable COPD patients the presence of microorganisms in their lower airways may cause harmful effects and induce chronic low-grade airway inflammation leading to increased exacerbation frequency, an accelerated decline in lung function and impaired health-related quality of life. Besides intraluminal localisation in the distal airways, bacteria can be found in the bronchial walls and parenchymal lung tissue of COPD patients. Therefore, the isolation of pathogenic bacteria in stable COPD should be considered as a form of chronic infection rather than colonisation. This new approach may have important implications for the management of patients with COPD. ª 2012 Elsevier Ltd. All rights reserved.

The role of microorganisms, especially bacteria, in the pathogenesis of chronic obstructive pulmonary disease (COPD) has been the focus of interest for several decades, although many questions remain to be answered. While in the 1950s and 1960s microorganisms were considered among the main aetiologic factors in COPD, and in the 1970s and 1980s their role was minimised, interest in this subject has rekindled in recent years with the introduction of new research techniques which have provided interesting and rather surprising discoveries. The difficulties and limitations of the microbiological assessment of different respiratory samples, the unclear significance of isolation of the same pathogens during both stable COPD and exacerbations and the absence of a standardised definition of COPD exacerbation are only some of the "problems" faced when investigating this issue and will be addressed in depth in this review. Another topic that will be discussed in detail is the significance of the presence of microorganisms, particularly bacterial, in the distal airways during stable COPD, which has recently become of increasing interest due to the emerging evidence that microorganisms may have an active role in the evolution of the disease.

Microorganisms are one of the main aetiologic factors involved in exacerbations of COPD. 1e13 In contrast, understanding of their role during stable phases of the disease is still incomplete, although some studies have suggested that they actively contribute to chronic airway inflammation leading to the progression of COPD. 13e19 Our knowledge of the bacterial species that can be found in the lower airways in stable COPD is based on qualitative and quantitative cultures of spontaneous or induced sputum samples, bronchoscopic protected specimen brush (PSB), as well as bronchial lavage (BL) and bronchoalveolar lavage (BAL) samples. 16e20 Novel, nonculture detection methods have recently been introduced in respiratory research, although broader use remains limited by their cost. These nonculture-based techniques include polymerase chain reaction (PCR) for the detection of microbial nucleic acid in respiratory specimens, 21, 22 molecular typing based on polyacrylamide and pulsedfield gel electrophoresis to distinguish different bacterial strains, 3, 22, 23 in situ hybridisation and immunofluorescence microscopy for detection of intracellular microorganisms in bronchial biopsy specimens. 24 Although sputum samples are easier to collect, these samples are mainly obtained from the large airways which are often contaminated by upper airway microbial flora, thereby reducing the reliability of the culture. In addition, PCR studies to detect bacterial nucleic acid have demonstrated false negatives with sputum cultures. 21, 22 In contrast, contamination by upper airway flora is avoided with the use of PSB, BL and BAL culture samples, but the use of fiberoptic bronchoscopy has inherent risks and cost. Additionally, bronchoscopic methods are unsuitable when repeated sampling is required, such as in longitudinal studies.

Another point that should be taken into consideration regarding colonisation is the cut-off value to define a positive culture, which, in most cases, is arbitrary. The thresholds for positive cultures used in most of the recently published studies are as follows: 10 2 or 10 5 colonyforming units/millilitre (CFU/ml) for sputum, 14, 17, 18, 25 10 2 CFU/ml for BL, 26 and 10 2 or 10 3 CFU/ml for PSB and BAL samples. 2,16,19,27e33 Bacterial species isolated from respiratory specimens are usually divided into two groups: potentially pathogenic microorganisms (PPMs) and non-potentially pathogenic microorganisms (non-PPMs). 16 16, 28, 34 Non-PPMs are usually not involved in respiratory infections in immunocompetent individuals; they belong to the normal oropharyngeal or gastrointestinal flora and include bacteria such as Corynebacterium spp., Neisseria spp., Enterococcus spp., coagulase-negative Staphylococcus spp. and Streptococcus viridans group and fungi such as Candida spp. 28, 32 The distribution of bacterial species into PPMs and non-PPMs may change over time in accordance with the evidence emerging. For example M. catarrhalis, previously known as Neisseria catarrhalis or Branhamella catarrhalis, was first considered as a non-PPM 35 but is now deemed as a PPM. 16, 23, 28, 34 The opposite situation might occur in the near future with H. haemolyticus and H. parainfluenzae, since recent findings have suggested their pathogenic potential to be much lower in comparison to other PPMs 4, 18, 36, 37 and some authors have already started to categorise them as non-PPMs. 33 2,18,25,27,34,38e40 while Pseudomonas spp. predominantly appear in more advanced disease. 17, 26 However, it is not unusual for more than one pathogen to simultaneously be isolated in the same patient. 2, 17, 25, 40 It is commonly believed that the lower respiratory tract of healthy non-smoking individuals is sterile, but some investigators have shown that lower airways of healthy subjects can also be colonised, 2, 16, 26, 28 although the colonisation rate is relatively low (4e40%) and caused mainly by non-PPMs (Tables 1 and 2 ). The exception is the study by Weinreich et al. 26 in which even 90% of healthy subjects (current smoking status unknown) had positive cultures of BL samples, although PPMs were isolated in only 10% ( Table 2) .

The rates of positive cultures in stable COPD vary depending on the sampling technique and the cut-off points employed. In the studies using sputum samples up to 100% of cultures were positive for any bacteria, while 38e74% were positive for PPMs (Table 3) . 14, 17, 18, 25, 39, 40 With PSB samples, the colonisation rate was somewhat lower, as expected, ranging from 22 to 83%, with PPMs isolated in 25e31% (Table 1) . 2,19,27e31 Similarly, BAL and BL cultures were positive in 13e89% of cases, with PPMs isolated in 33e43% (Table 2) . 16, 19, 26, 28 In most of the studies investigating distal airway colonisation in COPD, patients with previously proven bronchiectasis were excluded from the analysis. After the introduction of high-resolution computed tomography (HRCT) in the routine clinical practice, it has become clear that bronchiectasis of different degrees and extent is a common feature in COPD patients. 41, 42 Therefore, it is expected that the prevalence rate of bronchial colonisation in COPD could be even higher than suggested by the previously mentioned studies. In agreement with this presumption, the colonisation rate with PPMs was of up to 63% in the two studies in which bronchoscopic sampling was preformed in stable patients with bronchiectasis and COPD (Tables 1 and 2). 26, 32 Furthermore, in the study on stable COPD by Patel et al., 41 after excluding patients with previously diagnosed or clinically evident bronchiectasis, up to 50% of the study population fulfilled radiological criteria for bronchiectasis on HRCT and a positive correlation was found between lower lobe bronchiectasis, distal airway colonisation and bronchial inflammation. In a more recent study by Martinez-Garcia et al. 42 the prevalence of subclinical bronchiectasis in stable COPD was even higher (58%), and was significantly associated with a higher rate of bronchial colonisation and increased systemic inflammation measured by fibrinogen plasma levels.

The sensitivity of the novel, nonculture-based techniques to detect the presence of microorganisms is even greater. It has recently been demonstrated that with the use of PCR techniques, microbial nucleic acid can be extracted from a certain proportion of culture negative respiratory specimens. 21, 22 Assuming that nucleic acid represents viable bacteria, this would indicate even higher rates of colonisation than culture findings have suggested. Additionally, some microorganisms are able to invade and survive within airway epithelial cells and macrophages. 43, 44 With the use of in situ hybridisation and immunofluorescence microscopy for the detection of intracellular NTHi in bronchial biopsies, this microorganism was found in 33% and 87% of stable and severely exacerbated chronic bronchitis patients, respectively, but not in healthy adults. 24 The most frequently identified risk factors for colonisation with PPMs are current or previous smoking, 25,30,31 impaired lung function defined by a reduction in FEV 1 and/or forced vital capacity (FVC), 2,30,31 comorbid conditions, 25 increased rate of previous exacerbations 25, 39 and the presence of bronchiectasis. 26, 42 Purulent sputum and an increased degree of dyspnoea are also recognised as clinical indicators of positive sputum cultures for PPMs in stable COPD. 25 

The hostepathogen interaction is complex but crucial for the establishment and proliferation of microorganisms in the lower airways. This interaction is best described for NTHi and involves adherence to mucous membranes and extracellular matrix, damage to epithelial cells, ciliotoxic activity, an increase in mucin production, as well as complex mechanisms of evading host immune defences such as invasion into the epithelial cells, production of IgA proteases and antigenic heterogeneity. 44, 45 Some host factors such as reduced mucociliary clearance, mucus hypersecretion and bronchiectasis are also involved, 26 although it is not always clear whether some these features are really risk factors for acquiring bacteria or their consequence. Recent findings have stressed the role of innate immunity impairment in COPD, which among others, may manifest as defective phagocytosis and hyporesponsiveness of alveolar macrophages to bacterial antigens, leading to reduced clearance of bacterial pathogens and subsequent predisposition to colonisation and infection. 46, 47 COPD is characterised by different degrees of chronic inflammation affecting the large and small airways as well as the lung parenchyma and pulmonary vasculature. 29, 48, 49 Considering COPD as an inflammatory disorder, several studies have attempted to clarify the impact of bacterial colonisation in mediating this inflammatory process, beyond the effect of cigarette smoking. Bacteria release molecules with potent proinflammatory effects such as endotoxins (e.g. lipooligosaccharide of NTHi), outer membrane lipoproteins (e.g. outer membrane protein , which further lead to recruitment and activation of neutrophils, macrophages and other inflammatory cells. 51e54 The neutrophils, which prevail in the bronchial secretions of COPD patients and healthy smokers, 19 are recruited from the circulation and activated in response to chemoattractants, particularly IL-8 and leukotriene B4 (LTB4) via adhesion molecules, such as E-selectin and intercellular adhesion molecule (ICAM)-1, expressed on the vascular endothelium. The activated neutrophils degranulate releasing myeloperoxidase and different types of proteinases (elastase, cathepsin G, proteinase 3, matrix metalloproteinase), which together participate in various aspects of tissue damage. 38 Colonised COPD patients have higher concentrations of inflammatory cytokines, neutrophils and their products in respiratory secretions in comparison with non-colonised patients with a similar degree of airflow obstruction, which would indicate a higher level of airway inflammation induced by bacteria. 15, 16, 40 Different bacterial species and even different strains of the same species differ in virulence and inflammatory potential. 4, 17, 55 In the study by Hill et al., 17 P. aeruginosa was recognised as the most potent inducer of inflammation followed by NTHi, whereas M. catarrhalis provoked a significantly milder reaction. Additionally, Sethi et al. 4 demonstrated the significant inflammatory potential of NTHi and M. catarrhalis, while H. parainfluenzae-associated exacerbations had an inflammatory profile similar to PPM-negative exacerbations. Furthermore, there is an interspecies diversity in the duration of colonisation, e.g. M. catarrhalis is usually cleared from the respiratory tract efficiently, even without antibiotics, within a period of only one month, 23 while the carriage of NTHi and P. aeruginosa, particularly the mucoid strains, may last much longer. 18, 21, 22 Bacterial colonisation is a dynamic process with changes in pathogens, their strains and loads occurring over time. 3, 14, 18, 21, 23 It has been suggested that a change in bacterial strain and/or a rise in bacterial load can increase the degree of airway and systemic inflammation and trigger the onset of an exacerbation, 3,10,12,17,56,57 which will be discussed in more detail later. Most adults who acquire bacteria in their respiratory tract develop an immune response, as has been demonstrated in the study by Murphy et al. 23 in which 72% of episodes of acquisition of M. catarrhalis were followed by a systemic (serum IgG) and/or mucosal (sputum IgA) antibody response to the homologous strain. It is of clinical importance that colonised patients have worse health status, 40 increased exacerbation frequency as well as more symptoms during exacerbations. 39 Bacteria may also contribute to an accelerated decline in lung function and, consequently, to progression of COPD. This is supported by the study of Wilkinson et al., 14 in which a decline in FEV 1 was related to a change in the colonising bacterial type and a rise in airway bacterial load. This observation was confirmed by a more recent study in patients with moderate COPD, in which neutrophilic airway inflammation, mainly found in patients colonised by PPMs, was associated with more than a twofold increased risk of FEV 1 decline over the median decline during follow-up. 18 Bacteria may accelerate FEV 1 decline by both, directly increasing basal airway inflammation in the stable state, as well as by indirectly inducing more frequent and severe exacerbations. 14, 18, 39 In view of the above, it is clear that the isolation of PPMs from respiratory samples does not fulfil the definition of "colonisation", because it is associated with an inflammatory response and significant damage to the target organ. This is why it has recently been suggested that the term chronic bronchial infection would be more appropriate when addressing the presence of significant concentrations of PPMs in the lower airways of stable COPD patients. 13, 58 Chronic bronchial infection in COPD can be defined as the presence of PPMs in respiratory secretions that cause an inflammatory reaction manifested by the chronic production of coloured/purulent sputum. This syndrome can be accompanied by recurrent infective exacerbations and systemic manifestations in the form of malaise, febricula, asthenia or weight loss, similar to what has been described in patients with bronchiectasis. 59 In fact, most of these patients have significant bronchiectasis when studied by HRCT scan. In the study by Martinez-García et al. 42 the isolation of a PPM in sputum in a patient with stable COPD, together with a FEV 1 <50% predicted and the history of at least one hospital admission for an exacerbation the previous year were associated with a 99% probability of having bronchiectasis on CT scan. Conversely, the term colonisation should only be used to describe the isolation of non-PPMs from the distal respiratory tract, either in healthy subjects or in patients with a chronic airway disease.

Besides common bacteria, respiratory viruses and atypical bacteria in the form of chronic infection may also have an impact on the course of COPD. 8,48,60 Seemungal et al. 8 analysed nasal aspirates and blood samples of stable COPD patients by PCR and detected low-grade viral infection with respiratory syncytial virus (RSV) in 24% of patients, as well as infection with viruses other than RSV (dominantly rhinoviruses and coronaviruses) in 16% of patients. Patients in whom virus was detected were more likely to have increased exacerbation frequency as well as higher concentrations of serum IL-6 and plasma fibrinogen (potential predisposition to thrombotic events) when stable. 8 Furthermore, examining lung tissue of smokers with different degrees of emphysema, Retamales et al. 49 determined a 5-to 40-fold increase in the number of alveolar epithelial cells expressing adenoviral E1A protein in mild and severe emphysema, respectively, and suggested the impact of latent adenoviral infection on the amplification of cigarette smoke-induced lung inflammation which is present in severe emphysema. In addition to promoting an inflammatory process, lower respiratory viral or atypical bacterial infection may enhance the susceptibility of the airways to other pathogens. 60, 61 One example is chronic Chlamydophila pneumoniae infection in COPD patients, which has been associated with a higher rate of airway colonisation with common bacteria, frequent exacerbations and more severe functional impairment. 60 

Exacerbations are relatively frequent events in the course of COPD, especially in moderate-to-severe disease, with a significant impact on health status, quality of life, 62, 63 disease progression, 64 mortality, 65, 66 health-care utilisation and costs. 67, 68 Before discussing the role of microorganisms in the exacerbation of COPD (ECOPD), it should be mentioned that there is still no standardised definition of ECOPD. 69, 70 The reason for this probably lies in the complex pathophysiology and the different aetiologic factors involved, as well as in the variety of clinical manifestations presented by these patients. The American Thoracic Society/European Respiratory Society (ATS/ERS) Task Force on COPD 71 defines ECOPD as an increase in respiratory symptoms over baseline that usually requires a change in therapy. Nonetheless, the most widely used clinical criteria for ECOPD are increased dyspnoea, sputum volume and sputum purulence as defined by Anthonisen et al. 72 based on the probability of response to antibiotic therapy.

Despite all the limitations in defining ECOPD, investigations preformed in recent years have sought to establish the underlying pathophysiological process of these events. In comparison to the stable state, there is an acute increase in the level of airway inflammation during periods of exacerbations, assessed by the rise in sputum inflammatory cells (neutrophils, eosinophils and lymphocytes) and different inflammatory mediators including IL-6, IL-8, LTB4, TNFa, neutrophil proteases, myeloperoxidase, eosinophil cationic protein (ECP) and RANTES (Regulated upon Activation, Normal T-cell Expressed and Secreted). 1,4,50,54,57,58,73e75 Intensified inflammation may induce airway mucosal oedema, bronchospasm and mucus hypersecretion, which further lead to increased respiratory symptoms. 12 The association between neutrophilic inflammation, sputum purulence and bacterial exacerbations is well established and provides a rationale for using sputum purulence as a clinical indicator of bacterial infection and the need for antibiotic therapy. 4, 10, 33, 74, 76, 77 Additionally, sputum neutrophilia positively correlates with the severity of an exacerbation assessed by the impairment in lung function and the level of hypoxia. 1 Inflammation in ECOPD is not only limited to the lower airways. There is also a certain degree of upper airway and systemic inflammation, which is proportional to the lower airway inflammation and is higher in bacterial exacerbations. 58, 73, 74, 76 Furthermore, the clinical severity of exacerbations is significantly correlated with the level of local and systemic inflammation. 57 Published data suggest that up to 70% of exacerbations are caused by respiratory infections including aerobic bacteria (40e60%), respiratory viruses (about 30%) and atypical bacteria (5e10%). 11, 78 Some authors have demonstrated polymicrobial aetiology in as much as 33% of exacerbations, being particularly important in the most severe cases. 1, 79, 80 Environmental factors including low temperature and air pollution (exposure to higher levels of black smoke particulate matter, sulphur dioxide, nitrogen dioxide and ozone) are considered as the cause of approximately 10% of ECOPD, depending on the season and geographical setting. 78,81e83 Furthermore, non-compliance with therapy and/or abrupt withdrawal of therapy are provocation factors in some exacerbations. 84 Nonetheless, in a certain proportion of ECOPD the aetiology remains unknown.

Considering bacterial exacerbations, NTHi, S. pneumoniae and M. catarrhalis are the most frequently isolated PPMs from respiratory secretions during exacerbations, similar to what occurs in the stable state. 1, 2, 27, 85 Other Gram-negative bacteria such as P. aeruginosa, Stenotrophomonas maltophilia and members of the Enterobacteriaceae family are more often present in patients with a greater degree of functional impairment, recent antibiotic or systemic steroid therapy, and in those with severe exacerbations. 85e87 Interestingly, PPMs are isolated more frequently and in higher loads during exacerbations compared to the stable state. They can be found in about 50% of exacerbated patients when using PSB samples (Table 1) , usually with >10 7 CFU/ml in sputum cultures and >10 3 CFU/ml in PSB cultures. 1, 2, 10, 27, 79 As mentioned previously, when searching for the presence of NTHi intracellularly in the bronchial mucosa in exacerbated chronic bronchitis, NTHI was detected more frequently in comparison with the stable state. 24 All these findings and the fact that the severity of bronchial inflammation is directly correlated with bacterial load 17 led to the development of the "fall and rise" or quantitative hypothesis of bacterial ECOPD. 10 Based on this hypothesis, symptoms of exacerbation appear when the inflammatory reaction caused by the increasing bacterial load in the airways exceeds a certain threshold, which is determined by a combination of bacterial and host factors. 10 On the other hand, recent findings based on molecular typing of bacterial isolates have suggested that the acquisition of new strains of bacteria or antigenic change in pre-existing strains are crucial in the pathogenesis of bacterial exacerbations, and that the change in the bacterial load with subsequent enhancement of inflammation are just secondary phenomena. 3, 12, 22, 34, 57 Following a cohort of ambulatory COPD patients during more than four years, Sethi et al. 3 demonstrated that the acquisition of a new strain of NTHi, S. pneumoniae and M. catarrhalis was associated with more than a two-fold higher risk for an exacerbation. In a more recent study of a similar design but with a longer follow-up, Murphy et al. 22 have shown that the same association between change in a strain and occurrence of exacerbations also exists for P. aeruginosa. It is suggested that after a new strain is acquired due to the absence of an effective host immune response, bacteria may intensively proliferate in the airways resulting in a higher bacterial load, more severe local and systemic inflammation and the development of symptoms of exacerbation. 12, 57 The immune response to the infecting strain, which develops after an ECOPD, is strain-specific and not protective against acquisition of new strains, 5,23,88,89 which may explain recurrent exacerbations even by the same species. 56 Moreover, this specific immune response provides indirect evidence that the particular microorganism was actually the cause of the exacerbation. 5, 23, 88, 89 However, a change in strain may not be the only mechanism of exacerbations. In the previously mentioned studies, 3, 22 only 33% and 43%, respectively, of the visits involving isolation of a new bacterial strain were associated with the onset of an exacerbation. Additionally, in both studies a certain proportion of exacerbations were diagnosed at visits in which the isolated bacteria did not belong to a new strain, and also some exacerbations occurred at visits without isolation of any bacterial pathogen. It seems that the increase in airway inflammation and clinical manifestations of exacerbation are the result of a complex hostepathogen interaction in which a change in a bacterial strain plays a central role, but other factors may influence as well, e.g. host defences, virulence capacity of different strains or bacterial species, the presence of microorganisms other than bacteria and non-microbial provocation factors, among others. 3, 12, 13, 36, 56, 90 Role of viruses and atypical bacteria in exacerbations of COPD The role of viruses and atypical bacteria in ECOPD has recently received increasing attention thanks to novel diagnostic techniques such as PCR and reverse transcription PCR (RT-PCR), which have a higher sensitivity in detecting these pathogens compared with previously established methods (cell cultures, serology). In a systematic review on the prevalence of viral infection in ECOPD 7 including eight studies using PCR and/or RT-PCR in sputum and nasal lavage fluid samples, the weighted mean prevalence of respiratory viral infection was 34%, being as high as 56% in one of these studies. 91 Picornavirus (especially rhinovirus) was most commonly detected, followed by influenza (prevalence depended on the vaccination status of the study population) and respiratory syncytial virus. Coronavirus, parainfluenza, adenovirus and human metapneumovirus were detected in significantly smaller percentages. 7, 8 Considering the clinical presentation, viral exacerbations have been associated with a higher total symptom count at presentation, a higher frequency of additional symptoms (cold, sore throat, increased dyspnoea, fever), slower recovery and frequent previous exacerbations. 8 Direct evidence of the causal relationship between viral infections and ECOPD has recently been obtained in the study by Mallia et al. 9 who demonstrated that experimental rhinovirus infection in subjects with COPD induces clinical and inflammatory changes similar to those seen in naturally occurring exacerbations. After infection with rhinovirus, COPD patients developed more severe and prolonged respiratory symptoms, greater lung function impairment and increased airway inflammation in comparison with healthy controls. These authors suggested that experimental rhinovirus infection may be used in the future as a human model of ECOPD. 9 Atypical bacteria such as C. pneumoniae, Mycoplasma pneumoniae and Legionella spp. are intracellular pathogens that share some characteristics of viruses. 78 Their contribution in the emergence of exacerbations is not completely clear because the data on their prevalence significantly differ depending on the diagnostic methods and study populations involved. 6,92e95 It is commonly accepted that atypical bacteria cause 5e10% of ECOPD, 11, 78 either as independent pathogens or, more frequently, as co-pathogens. 80, 93, 94 However, in several serologic studies, much higher proportions of exacerbated patients had evidence of a recent infection with C. pneumoniae, M. pneumoniae or Legionella spp. e up to 34%, 14% and 17%, respectively. 6,92e94 Polymicrobial aetiology is frequently found in the most severe ECOPD and manifests either as simultaneous coinfection, secondary bacterial after a viral infection or vice versa. 5, 79, 80 One of the proposed mechanisms of interaction between viruses and bacteria includes changes in the receptor molecules on the respiratory epithelial cells induced by one microorganism leading to increased susceptibility to the other microorganism. 13, 61 There is evidence that patients with polymicrobial exacerbations have more severe deterioration in lung function, a higher symptom count and longer hospitalisation. 1, 79 Is COPD a chronic infective disease?

Although smoking cessation is effective in slowing the accelerated decline in lung function, it has been observed that the inflammatory process in the lungs of patients with COPD continues after smoking cessation, and in some aspects may even increase, contrary to the case in healthy ex-smokers whose airway inflammation usually decreases. 96, 97 Furthermore, inflammation in COPD patients is not limited to their lungs; namely, they have persistent systemic inflammation as well. 98 Some of the suggested promoters of this on-going inflammation in ex-smoking COPD patients are microorganisms, autoimmunity, inflammation as part of a repair process, recovery of the proinflammatory capacity of epithelial cells after smoking cessation or disappearance of anti-inflammatory factors such as carbon monoxide from cigarette smoke. 96 However, after review of the evidence, microorganisms emerge as the most likely "candidates" to perpetuate bronchial inflammation. In favour of this hypothesis, Moller et al. 99 detected H. influenzae more frequently in tissue sections of lungs from patients with COPD and cystic fibrosis than from others when analysing lung explants from transplant recipients with different end-stage pulmonary diseases. Their results indicate a generalised distribution of H. influenzae in the lungs of these patients, with the presence of bacteria in the epithelium and submucosa of the bronchi and bronchioles, parenchymal lung tissue (alveolar epithelium, interstitium, alveoli), as well as in the visceral pleura. 99 Other in vitro and in vivo studies have confirmed the ability of bacteria to invade lung tissue and persist therein. 24, 43 Apart from the frequent intraluminal localisation of bacteria in the airways of COPD patients, it has been suggested that such "tissue reservoir" protects these patients from the circulating antibiotics and effective host immune defences may serve as an endogenous source for recurrent infections as well as a chronic inflammatory stimulus. 43, 52 The hypothesis of chronic microbial stimulation is supported by the histological changes observed in the lungs of COPD patients. Namely, besides tissue remodelling, progression of the disease leads to increased infiltration of the small airways by the lymphocytes and their organisation into lymphoid follicles, probably as an adaptive immune response to persistent microbial stimulation. 100 Evidence suggests that, together with smoking, microorganisms play a significant role in the development and progression of COPD. The sequence of events in the pathogenesis of COPD with microbial involvement is summarised in Fig. 1 . The most important difference with other chronic infective disease is that COPD does not involve only one causative pathogen but rather there is a change in the pathogens, their strains and loads occurring over time. Whether this influence of infection exists for all COPD patients or only for those with an "infective phenotype" still needs to be established since most of the previous longitudinal studies investigating this issue have only included COPD patients with chronic bronchitis. In fact, even exacerbations themselves may have different phenotypes. Bacterial exacerbations present with a particular inflammatory profile that is different from the viral, the so-called eosinophilicpredominant and the pauciinflammatory. 101 Interestingly, the bacterial exacerbation phenotype can be identified from the stable state in patients with an "infective phenotype" and these patients will develop the same type (or phenotype) of bacterial exacerbation in successive episodes. 101 This infective phenotype of COPD could be described as patients with chronic production of coloured sputum during a stable state, recurrent bacterial exacerbations and frequently associated bronchiectasis. In other words, the infective phenotype in COPD refers to patients with the syndrome of chronic bronchial infection.

However, many aspects of the relationship between infection (acute and chronic) and COPD require further research, e.g. the significance of simultaneous isolation of multiple bacterial strains, possible cooperation of PPMs and non-PPMs in disease progression and the development of antibiotic resistance, mechanisms of interactions of different pathogens in polymicrobial infections as well as the relation between microbial and environmental factors in the pathogenesis of exacerbations. The use of novel, molecular, cellular and immunologic techniques is crucial for progress in this research. In addition, efforts should be made to seek new, reliable, non-invasive methods for detection of lower airway infection/inflammation in order to avoid limitations of sputum cultures and the inconvenience of bronchoscopic sampling. Further evidence on the impact of bacteria in COPD can be expected from the results of the currently ongoing clinical trials on antibiotics in stable COPD. 102, 103 Finally, the relevance of the described microbiota on lung health must be established. Molecular culture-independent techniques have identified bacteria previously not amenable to culture. Analysis of the highly conserved 16S rRNA gene has been used to assign phylogeny and allows a picture of the complete microbial community in an environment (the bronchial tree) to be constructed, offering a more comprehensive analysis than classical culture-based techniques. 104 The number of studies examining the lower airways microbiome is limited and there is some overlap between bacteria seen in COPD and healthy individuals 105 ; however, a recent study has reported a significantly different bacterial community (microbiome) in patients with very severe COPD compared with nonsmokers, smokers and patients with cystic fibrosis. 106 Further studies are clearly needed to understand the role of these microbiomes in healthy individuals and patients with COPD. Figure 1 The impact of microbial infection on the pathogenesis of COPD, both in the stable state and in exacerbations. Since the current evidence for the role of atypical bacteria is incomplete, they are presented with a dashed line. COPD: chronic obstructive pulmonary disease; PPM: potentially pathogenic microorganism.

Sharp & Dohme and Nycomed and grant support from Talecris.

Zinka Matkovic has no conflict of interest to disclose.

Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations

Microbiologic determinants of exacerbation in chronic obstructive pulmonary disease

New strains of bacteria and exacerbations of chronic obstructive pulmonary disease

Airway inflammation and etiology of acute exacerbations of chronic bronchitis

Infectious exacerbations of chronic obstructive pulmonary disease associated with respiratory viruses and non-typeable Haemophilus influenzae

Infectious etiologies in acute exacerbation of COPD

Prevalence of viral infection detected by PCR and RT-PCR in patients with acute exacerbation of COPD: a systematic review

Respiratory viruses, symptoms, and inflammatory markers in acute exacerbations and stable chronic obstructive pulmonary disease

Experimental rhinovirus infection as a human model of chronic obstructive pulmonary disease exacerbation

Exacerbations of chronic obstructive pulmonary disease: when are bacteria important?

Infectious etiology of acute exacerbations of chronic bronchitis

Pathogenesis of bacterial exacerbations of COPD

Infection in the pathogenesis and course of chronic obstructive pulmonary disease

Airway bacterial load and FEV 1 decline in patients with chronic obstructive pulmonary disease

Airway inflammation in nonobstructive and obstructive chronic bronchitis with chronic Haemophilus influenzae airway infection. Comparison with noninfected patients with chronic obstructive pulmonary disease

Airway inflammation and bronchial bacterial colonisation in chronic obstructive pulmonary disease

Association between airway bacterial load and markers of airway inflammation in patients with stable chronic bronchitis

Variability and effects of bronchial colonisation in patients with moderate COPD

Airway inflammation and bronchial microbial patterns in patients with stable chronic obstructive pulmonary disease

The role of bacteria in airway inflammation in exacerbations of chronic obstructive pulmonary disease

Persistent colonization by Haemophilus influenzae in chronic obstructive pulmonary disease

Pseudomonas aeruginosa in chronic obstructive pulmonary disease

Moraxella catarrhalis in chronic obstructive pulmonary disease: burden of disease and immune response

Nontypeable Haemophilus influenzae in the lower respiratory tract of patients with chronic bronchitis

Colour of sputum is a marker for bacterial colonisation in chronic obstructive pulmonary disease

Bacterial colonisation of lower airways in health and chronic lung disease

Bacterial infection in chronic obstructive pulmonary disease. A study of stable and exacerbated outpatients using the protected specimen brush

Bacterial colonization of distal airways in healthy subjects and chronic lung disease: a bronchoscopic study

Bronchial inflammation in chronic bronchitis assessed by measurement of cell products in bronchial lavage fluid

Risk factors for lower airway bacterial colonization in chronic bronchitis

Predisposing factors to bacterial colonization in chronic obstructive pulmonary disease

Bacterial colonisation in patients with bronchiectasis: microbiological pattern and risk factors

Bronchoscopic validation of the significance of sputum purulence in severe exacerbations of chronic obstructive pulmonary disease

Airway bacterial concentrations and exacerbations of chronic obstructive pulmonary disease

The bacteriology of chronic bronchitis

Haemophilus haemolyticus: a human respiratory tract commensal to be distinguished from Haemophilus influenzae

Haemophilus parainfluenzae infection of respiratory mucosa

Chronic obstructive pulmonary disease 6: the aetiology of exacerbations of chronic obstructive pulmonary disease

Relationship between bacterial colonisation and the frequency, character, and severity of COPD exacerbations

Impact of sputum bacteria on airway inflammation and health status in clinical stable COPD

Bronchiectasis, exacerbation indices, and inflammation in chronic obstructive pulmonary disease

Factors associated with bronchiectasis in chronic obstructive pulmonary disease patients

Survival of nontypeable Haemophilus influenzae in macrophages

Nontypeable Haemophilus influenzae: pathogenesis and prevention

Virulence factors in the colonization and persistence of bacteria in the airways

Impaired alveolar macrophage response to Haemophilus antigens in chronic obstructive lung disease

Defective macrophage phagocytosis of bacteria in COPD

Amplification of inflammation in emphysema and its association with latent adenoviral infection

Airway inflammation during stable and acutely exacerbated chronic obstructive pulmonary disease

A novel role for IkB kinase (IKK) a and IKKb in ERK-dependent up-regulation of MUC5AC mucin transcription by Streptococcus pneumoniae

Induction of proinflammatory cytokines from human respiratory epithelial cells after stimulation by nontypeable Haemophilus influenzae

Outer membrane protein P6 of nontypeable Haemophilus influenzae is a potent and selective inducer of human macrophage proinflammatory cytokines

Factors influencing airway inflammation in chronic obstructive pulmonary disease

Chemokines in bronchiolar epithelium in the development of chronic obstructive pulmonary disease

Persisting Haemophilus influenzae strains induce lower levels of interleukin-6 and interleukin-8 in H292 lung epithelial cells than nonpersisting strains

New developments in the pathogenesis of acute exacerbations of chronic obstructive pulmonary disease

Inflammatory profile of new bacterial strain exacerbations of chronic obstructive pulmonary disease

Infection as a comorbidity of COPD

Diagnosis and treatment of bronchiectasis

Chlamidia InterAction with COPD (CIAC) Study Group. Chlamydia pneumoniae and chronic bronchitis: association with severity and bacterial clearance following treatment

Respiratory viruses augment the adhesion of bacterial pathogens to respiratory epithelium in a viral species-and cell type-dependent manner

Effect of exacerbations on quality of life in patients with chronic obstructive pulmonary disease: a 2 year follow up study

Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease

Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease

Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease

Factors affecting survival of hospitalised patients with COPD

Pharmacoeconomic evaluation of acute exacerbations of chronic bronchitis and COPD

Epidemiology and costs of chronic obstructive pulmonary disease

European Respiratory Society Task Force on outcomes of COPD. Outcomes for COPD pharmacological trials: from lung function to biomarkers

The impact of using different symptom-based exacerbation algorithms in patients with COPD

European Respiratory Society Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper

Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease

Systemic and upper and lower airway inflammation at exacerbation of chronic obstructive pulmonary disease

Changes in bronchial inflammation during acute exacerbations of chronic bronchitis

Granulocyte inflammatory markers and airway infection during acute exacerbation of chronic obstructive pulmonary disease

Relationship of sputum color to nature and outpatient management of acute exacerbations of COPD

Sputum colour and bacteria in chronic bronchitis exacerbations: a pooled analysis

COPD exacerbations$2: aetiology

Effect of interactions between lower airway bacterial and rhinoviral infection in exacerbations of COPD

Bronchial microbial patterns in severe exacerbations of chronic obstructive pulmonary disease (COPD) requiring mechanical ventilation

Effect of temperature on lung function and symptoms in chronic obstructive pulmonary disease

Exacerbations of COPD: environmental mechanisms

Air pollution and daily admissions for chronic obstructive pulmonary disease in 6 European cities: results from the APHEA project

Calverley PMA for the ISOLDE Study Group. An observational study of inhaled corticosteroid withdrawal is stable chronic obstructive pulmonary disease

Study Group of Bacterial Infection in COPD. Relationship between bacterial flora in sputum and functional impairment in patients with acute exacerbations of COPD

Infective exacerbations of chronic bronchitis: relation between bacteriologic etiology and lung function

A prediction model for bacterial etiology in acute exacerbations of COPD

Strain-specific immune response to Haemophilus influenzae in chronic obstructive pulmonary disease

Systemic and mucosal antibody response to Moraxella catarrhalis after exacerbations of chronic obstructive pulmonary disease

Haemophilus influenzae from patients with chronic obstructive pulmonary disease exacerbation induce more inflammation than colonizers

Respiratory viruses in exacerbations of chronic obstructive pulmonary disease requiring hospitalisation: a case-control study

Chlamydia pneumoniae infection and acute exacerbation of chronic obstructive pulmonary disease (COPD)

Serological evidence of Mycoplasma pneumoniae infection in acute exacerbation of COPD

Serological evidence of Legionella species infection in acute exacerbation of COPD

Serological diagnosis of Chlamydia pneumoniae infection: limitations and perspectives

Effect of 1-year smoking cessation on airway inflammation in COPD and asymptomatic smokers

Ongoing airway inflammation in patients with COPD who do not currently smoke

Association between chronic obstructive pulmonary disease and systemic inflammation: a systemic review and a meta-analysis

Haemophilus influenzae in lung explants of patients with end-stage pulmonary disease

The nature of small-airway obstruction in chronic obstructive pulmonary disease

Acute exacerbations of chronic obstructive pulmonary disease. Identification of biologic clusters and their biomarkers

The benefits of long-term systemic antimicrobial therapy in chronic obstructive pulmonary disease

Efficacy of antibiotic therapy for acute exacerbations of mild to moderate COPD

Lung microbiology and exacerbations in COPD

The lung tissue microbiome in chronic obstructive pulmonary disease

Analysis of the lung microbiome in the "healthy" smoker and in COPD

Dr. Zinka Matkovic from the University Hospital Dubrava, Zagreb, Croatia, is the recipient of a joint European Respiratory Society/Spanish Society of Pneumology and Thoracic Surgery (ERS/SEPAR) LTRF fellowship 47-2010.